Benchmark raises Exact Sciences stock price target to $60 on cancer test launch

Published 30/09/2025, 14:48
Benchmark raises Exact Sciences stock price target to $60 on cancer test launch

Investing.com - Benchmark raised its price target on Exact Sciences (NASDAQ:EXAS) to $60.00 from $54.00 on Tuesday, while maintaining a Buy rating on the stock. Currently trading at $53.86, the company has received positive attention from analysts, with InvestingPro data showing 5 analysts recently revising earnings estimates upward.

The research firm's new price target represents 4x its 2026 EV/Revenue estimate, which aligns with the comparable group average.

Benchmark noted that Exact Sciences launched its Multi-Cancer Early Detection (MCED) test, called Cancerguard, on September 10 as a laboratory-developed test (LDT).

The cancer screening company's new test could provide upside to Benchmark's current 2026 estimates, according to the research firm.

Exact Sciences specializes in the development and commercialization of cancer screening and diagnostic tests, with Cancerguard now joining its product portfolio.

In other recent news, Exact Sciences has launched Cancerguard, a multi-cancer early detection blood test, now available in the United States. The test, priced at $689, can detect over 50 types of cancer, including pancreatic, ovarian, and lung cancers. Despite this innovation, several analyst firms have adjusted their price targets for Exact Sciences. BTIG lowered its price target to $60, citing a surprising deal with Freenome, while maintaining a Buy rating. Bernstein SocGen also reduced its target to $60, pointing to developments in the blood-based CRC screening program, despite Exact Sciences' strong quarterly results. RBC Capital lowered its target to $46 over growth concerns, even as the company reported a $40 million revenue beat and increased full-year guidance. TD Cowen adjusted its target to $66, describing the recent quarter as the "best Cologuard quarter in a while." These recent developments highlight both the company's innovation and the cautious stance of analysts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.